Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2025-04-20 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
2024年年度财务报告
Annual Report Classification · 95% confidence The document is titled as the 2024年度财务决算报告 (2024 Annual Financial Settlement Report) of 恩威医药股份有限公司, which includes detailed financial data such as revenue, net profit, cash flow, assets, liabilities, and financial ratios for the full fiscal year 2024. It also mentions the audit report issued by an accounting firm with an audit opinion on the financial statements. The content is comprehensive and contains actual financial statements and analysis for the full year, consistent with an Annual Report. The document length is 2951 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or certification. Therefore, it should be classified as an Annual Report (10-K).
2025-04-20 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '恩威医药股份有限公司2025 年第一季度报告' which translates to 'Enwei Pharmaceutical Co., Ltd. 2025 First Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes on financial metrics for the first quarter of 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. It is not an announcement or a brief summary but a full report with substantive financial data. The document is not audited, but that does not change its classification as an interim/quarterly report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2025-04-20 Chinese
独立董事2024年度述职报告（彭刚）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2024 Annual Work Report" for Enwei Pharmaceutical Co., Ltd. It details the independent director's duties, attendance at board and shareholder meetings, committee work, communication with auditors, and oversight of financial and governance matters during the 2024 fiscal year. The content focuses on the director's report on their activities and evaluations rather than presenting full financial statements or audit opinions alone. It is a detailed management-related report on governance and oversight activities by an independent director, which aligns with Board/Management Information filings. It is not a full Annual Report (10-K), Audit Report (AR), or a simple announcement. The document length and content confirm it is a substantive report rather than a brief announcement or certification. Therefore, the best fitting category is Board/Management Information (MANG).
2025-04-20 Chinese
2024年年度审计报告
Audit Report / Information Classification · 98% confidence The document is titled as an "审计报告" (Audit Report) for the fiscal year 2024 of 恩威医药股份有限公司. It contains detailed audit opinions, basis for audit, key audit matters, responsibilities of management and auditors, and extensive financial statements including consolidated and parent company balance sheets, profit and loss statements, and cash flow statements. The content is comprehensive and includes the auditor's detailed assessment and opinion on the financial statements, which is characteristic of a standalone audit report rather than a full annual report or other filing types. The document length is substantial (15,000 characters) and contains actual financial data and audit details, not just an announcement or certification. Therefore, the document fits the category of an Audit Report / Information (AR).
2025-04-20 Chinese
公司募集资金使用管理制度
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金使用管理制度" which translates to "Fundraising Capital Usage Management System" for Enwei Pharmaceutical Co., Ltd. It details the management, storage, usage, supervision, and responsibility related to the company's raised funds. The content includes regulatory references, internal control procedures, and compliance with laws regarding the use of raised capital. It is a detailed policy document about the management and use of capital raised through stock issuance, not a financial report or announcement of results. It does not contain financial statements or earnings data, nor is it a simple announcement or certification. It is a regulatory compliance and internal management document related to capital usage, which fits best under Capital/Financing Update (CAP) as it concerns the management and use of raised capital funds.
2025-04-20 Chinese
关于修订公司部分内部控制制度的公告
Governance Information Classification · 95% confidence The document is an announcement from the company regarding revisions to some internal control systems and related governance documents. It mentions board and supervisory committee meetings where these revisions were approved. The document does not contain detailed financial data, audit results, or full reports but rather informs about governance-related changes and points to where the full documents can be found. It also references compliance with company law and listing rules, indicating governance and internal control updates. This fits best under Governance Information (CGR) as it details changes to internal rules and governance practices rather than being a full report or a simple announcement of a report publication.
2025-04-20 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.